Author(s): Rosenberg SA, Yang JC, Restifo NP, Rosenberg SA, Yang JC, Restifo NP, Rosenberg SA, Yang JC, Restifo NP, Rosenberg SA, Yang JC, Restifo NP
Abstract Share this page
Abstract Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6\%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
This article was published in Nat Med
and referenced in Immunotherapy: Open Access